BeOne Medicines AG develops cancer medicines and conducts research and clinical development in oncology, focusing on targeted therapies for hematologic malignancies and solid tumors. The company advances a pipeline of investigational therapies, runs global clinical trials and collaborates on development, manufacturing and patient access.
AI-generated
Offering
Products & services
Industry:Holding Companies
Outbound Leads by COHAGA
Looking for direct email addresses and phone numbers?
Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.
Cancer medicines, including BRUKINSA (zanubrutinib), TEVIMBRA (tislelizumab-jsgr) and BEQALZI (sonrotoclax).
Clinical trials
Clinical trials in haematology, lung cancer, stomach cancer, breast cancer and other indications; opportunities to participate and obtain information for patients and healthcare professionals.
Research and development
Research and development for oncology therapies with a focus on haematology and solid tumours, as well as approaches such as CDACs and antibody drug conjugates.
Patient Support Program
Personalised support for prescribed patients, including insurance and co-pay assistance, education and help with financial, advisory and transportation needs.
Expanded Access Program
Access to investigational products for patients with no other treatment options and not participating in a clinical trial, in compliance with local regulations.
Partnerships for development, manufacturing and access
Partnerships with biotech, pharma and academic partners for process design, manufacturing, regulatory strategy, global clinical trials and market access.
Manufacturing of medicines
Manufacturing of small molecules, biologics, antibody drug conjugates, oral dosage forms and injectables, as well as analytical and process development.
Treatment of haematological malignancies
Treatment of B-cell disorders and other haematological malignancies with agents such as Zanubrutinib, Sonrotoclax and Blinatumomab in the pipeline or approved.
Treatment of solid tumours
Treatment of solid tumours, including lung, gastrointestinal, breast and gynaecological cancers, with approved and development-stage agents.
Comparisons
BeOne Medicines AG in comparison
Soon
Industry comparisons are coming soon
We're preparing industry comparisons that rank BeOne Medicines AG by reviews, experience and specialisations.
Knowledge
No knowledge articles yet
Once BeOne Medicines AG has claimed this profile, we'll publish editorial articles and case studies here together.